153 related articles for article (PubMed ID: 21673355)
61. Cost-effectiveness analysis of repeated self-sampling for HPV testing in primary cervical screening: a randomized study.
Aarnio R; Östensson E; Olovsson M; Gustavsson I; Gyllensten U
BMC Cancer; 2020 Jul; 20(1):645. PubMed ID: 32660432
[TBL] [Abstract][Full Text] [Related]
62. HPV detection in a self-collected vaginal swab combined with VIA for cervical cancer screening with correlation to histologically confirmed CIN.
Kamal EM; El Sayed GA; El Behery MM; El Shennawy GA
Arch Gynecol Obstet; 2014 Dec; 290(6):1207-13. PubMed ID: 25009070
[TBL] [Abstract][Full Text] [Related]
63. New technologies for cervical cancer screening.
Brown AJ; Trimble CL
Best Pract Res Clin Obstet Gynaecol; 2012 Apr; 26(2):233-42. PubMed ID: 22119058
[TBL] [Abstract][Full Text] [Related]
64. Screening trial of human papillomavirus for early detection of cervical cancer in Santiago, Chile.
Ferreccio C; Barriga MI; Lagos M; Ibáñez C; Poggi H; González F; Terrazas S; Katki HA; Núñez F; Cartagena J; Van De Wyngard V; Viñales D; Brañes J
Int J Cancer; 2013 Feb; 132(4):916-23. PubMed ID: 22684726
[TBL] [Abstract][Full Text] [Related]
65. [Evaluation of the effectiveness of BMRT-HPV for cervical cancer screening].
Duan LF; Du H; Wang C; Huang X; Qu XF; Duan XZ; Liu Y; Shi B; Zhang W; Wei LH; Belinson L; Wu RF
Zhonghua Fu Chan Ke Za Zhi; 2020 Oct; 55(10):708-715. PubMed ID: 33120484
[No Abstract] [Full Text] [Related]
66. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program.
Lazcano-Ponce E; Lörincz AT; Salmerón J; Fernández I; Cruz A; Hernández P; Mejia I; Hernández-Avila M
Cancer Causes Control; 2010 Oct; 21(10):1693-700. PubMed ID: 20617376
[TBL] [Abstract][Full Text] [Related]
67. Cost-effectiveness of 21 alternative cervical cancer screening strategies.
Chuck A
Value Health; 2010; 13(2):169-79. PubMed ID: 19804436
[TBL] [Abstract][Full Text] [Related]
68. Organised screening for cervical cancer in France: a cost-effectiveness assessment.
Barré S; Massetti M; Leleu H; De Bels F
BMJ Open; 2017 Oct; 7(10):e014626. PubMed ID: 28988162
[TBL] [Abstract][Full Text] [Related]
69. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions.
Serrano B; de Sanjosé S; Tous S; Quiros B; Muñoz N; Bosch X; Alemany L
Eur J Cancer; 2015 Sep; 51(13):1732-41. PubMed ID: 26121913
[TBL] [Abstract][Full Text] [Related]
70. Implementation of HPV-based Cervical Cancer Screening Combined with Self-sampling Using a Midwifery Network Across Rural Greece: The GRECOSELF Study.
Agorastos T; Chatzistamatiou K; Tsertanidou A; Mouchtaropoulou E; Pasentsis K; Kitsou A; Moysiadis T; Moschaki V; Skenderi A; Katsiki E; Aggelidou S; Venizelos I; Ntoula M; Daponte A; Vanakara P; Garas A; Stefos T; Vrekoussis T; Lymberis V; Kontomanolis EN; Makrigiannakis A; Manidakis G; Deligeoroglou E; Panoskaltsis T; Decavalas GO; Michail G; Kalogiannidis I; Koukoulis G; Zempili P; Halatsi D; Truva T; Piha V; Agelena G; Chronopoulou A; Vaitsi V; Chatzaki E; Paschopoulos M; Adonakis G; Kaufmann AM; Hadzidimitriou A; Stamatopoulos K
Cancer Prev Res (Phila); 2019 Oct; 12(10):701-710. PubMed ID: 31427275
[TBL] [Abstract][Full Text] [Related]
71. [Guidelines for application of molecular tests identyfying HR HPV DNA in the prevention of cervical cancer. Statement of experts from PGS (PTG) and NCLD (KIDL)].
;
Ginekol Pol; 2013 May; 84(5):395-9. PubMed ID: 23819408
[TBL] [Abstract][Full Text] [Related]
72. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions.
Sellors JW; Lorincz AT; Mahony JB; Mielzynska I; Lytwyn A; Roth P; Howard M; Chong S; Daya D; Chapman W; Chernesky M
CMAJ; 2000 Sep; 163(5):513-8. PubMed ID: 11006761
[TBL] [Abstract][Full Text] [Related]
73. [Combining high-risk human papillomavirus DNA test and cytological test to detect early cervical dysplasia].
Qian DY; Cen JM; Wang D; Zeng RH; Lin AH; Shu YH; Hong DH; Huang ZH
Zhonghua Fu Chan Ke Za Zhi; 2006 Jan; 41(1):34-7. PubMed ID: 16635326
[TBL] [Abstract][Full Text] [Related]
74. [Prevention and treatment of cervical cancer, it is a long-term and arduous task].
Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2013 Apr; 48(4):304-6. PubMed ID: 23902818
[No Abstract] [Full Text] [Related]
75. Cervical cancer screening in high- and low-resource countries: implications and new developments.
Hoppenot C; Stampler K; Dunton C
Obstet Gynecol Surv; 2012 Oct; 67(10):658-67. PubMed ID: 23112073
[TBL] [Abstract][Full Text] [Related]
76. [HPV testing in prevention of cervical cancer: practices and current trends].
Monsonego J
Ann Biol Clin (Paris); 2013 Nov; 71():27-32. PubMed ID: 24235325
[TBL] [Abstract][Full Text] [Related]
77. Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway.
Burger EA; Ortendahl JD; Sy S; Kristiansen IS; Kim JJ
Br J Cancer; 2012 Apr; 106(9):1571-8. PubMed ID: 22441643
[TBL] [Abstract][Full Text] [Related]
78. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
79. Human papillomavirus screening in north Indian women.
Pandey S; Mishra M; Chandrawati
Asian Pac J Cancer Prev; 2012; 13(6):2643-6. PubMed ID: 22938435
[TBL] [Abstract][Full Text] [Related]
80. Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in cervical cancer screening in Switzerland.
Vassilakos P; Poncet A; Catarino R; Viviano M; Petignat P; Combescure C
Gynecol Oncol; 2019 Apr; 153(1):92-99. PubMed ID: 30718124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
